Martínez-Castellanos and colleagues evaluated ocular function, neurodevelopment, and growth in infants treated with intravitreal bevacizumab injections for retinopathy of prematurity (ROP) during a ...
CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...
Credit: Getty Images. The Agency could not approve the BLA due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. The Food and ...
Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026, for Outlook Therapeutics’ ...
Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, ...
Following a request for judicial review by drugmakers Bayer and Novartis, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement clarifying that Roche's Avastin ...
This month, the European Medicines Agency (EMA) gave marketing authorization to bevacizumab-vikg (Lytenava, Outlook Therapeutics) for the treatment of neovascular (wet) age-related macular ...
The FDA has issued an alert that repackaged intravitreal injections of the drug Avastin have caused at least a dozen serious eye infections in the Miami area, according to an FDA news release. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results